Beijing Shionogi Pharmaceutical Technology Limited
Basic information
- Head office
- Room 07, 20th Floor, Jinghui Building, No. 118 Jianguo Road, Chaoyang District, Beijing
- Chief executive
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- End date
Websites
Business
Related companies
—
Network
History
Founder Saburo Shiono, established the drugstore Shiono Saburo Store in Dosho-machi, Osaka, selling traditional Chinese and Japanese medicines![]()
Saburo Shionogi founded the drug wholesaler "Shiono Saburo Store" at 3-chome 12, Doshomachi, Osaka, on his 24th birthday, March 17, 1878.![]()
Manufactured and sold the first proprietary new drug, antacid "Antachidin," and registered the trademark with a weight mark![]()
Saburo's second son, Nagajiro, began trial manufacturing of an antacid and succeeded in productization. This stomach medicine "Antadizen" became the first new drug developed in-house.![]()
Shiono Saburo Store registered the balance scale mark as a trademark, symbolizing trust and credibility.![]()
Saburo built the pharmaceutical factory "Shiono Pharmaceutical Factory" in Nishinari District, Osaka Prefecture, which started full operation in 1910.![]()
The new heart medicine "Digitammin" was launched through the introduction by the head of the pharmaceutical factory.![]()
Merged Shiono Saburo Store and Shiono Pharmaceutical Plant, reorganized into Shiono Pharmaceutical Co., Ltd.![]()
In 1919, after World War II, the company merged with Shiono Saburo Store and Shiono Pharmaceutical Factory to establish "Shiono Saburo Co., Ltd.".![]()
Established Kusatsu Factory (Amagasaki City, Hyogo Prefecture) (now Kusatsu Business Office), and set up a research laboratory within the factory![]()
Management deteriorated due to post-war inflation and rising prices; Saburo promoted technology transfer and cost reduction to improve management.![]()
Inherited the corporate philosophy of producing better products, selling accurately, and improving profits and living standards through technological development.![]()
Established a development subsidiary in the US and started collaboration with GlaxoSmithKline to narrow research areas and accelerate development.![]()
Built the Central Research Institute in Fukushima-ku, Osaka (now consolidated into the Pharmaceutical Research Center)![]()
Established the Animal Drugs Department (transferred in 2002), Plant Drugs Department (transferred in 2001), and clinical testing laboratory (transferred in 2002), and established Taiwan Shiono Pharmaceutical Co., Ltd.![]()
Construction of Shionogi Shibuya Building (Tokyo Shibuya Ward), construction of new drug research institute (Osaka Toyonaka City) (current: Pharmaceutical Research Center)![]()
Construction of Medical Science Research Institute (within Settsu Factory site) (current: Pharmaceutical Research Center), launch of oxacefem-based antibiotic "Furmarin"![]()
Establishment of Shionogi General Service Co., Ltd. (current: Shionogi Business Partner Co., Ltd.), acquisition of capsule business from Eli Lilly & Co. (sold in 2005)![]()
Establishment of Shionogi Action Charter (revised in 2012), founding of Omori Pharmaceutical Co., Ltd. (sold in 2002), establishment of Bushu Pharmaceutical Co., Ltd. (sold in 2010)![]()
Establishment of Shionogi USA, Inc. (current: Shionogi Inc.), establishment of overseas JV: Shionogi-GlaxoSmithKline Pharmaceuticals LLC, and start of joint research and development of HIV infection treatment drugs![]()
Start of 2nd Mid-term Management Plan, launch of high cholesterol treatment drug "Crestor", launch of carbapenem antibiotic "Fynbax"![]()
Acquisition of US Sciele Pharma, Inc. (current: Shionogi Inc.), opening of joint research facility with Hokkaido University, Shionogi Drug Discovery Innovation Center, launch of antihypertensive drug "Irbetan", treatment for common acne "Difelin", idiopathic pulmonary fibrosis drug "Pirespa"![]()
Start of 3rd Mid-term Management Plan, establishment of Shionogi Techno Advance Research Inc., opening of Osaka University Graduate School of Medicine PET Molecular Imaging Center, launch of anti-influenza drug "Lapiakta", antidepressant "Simbalta"![]()
Acquisition of Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited, construction of new research building SPRC4 within Pharmaceutical Research Center (SPRC), consolidating drug discovery research functions![]()
Establishment of European subsidiary Shionogi Limited (UK), signing of contract with Vibe Healthcare for HIV infection treatment drugs, launch of cancer pain treatment injection "OkiFast", launch of antihypertensive drug "Aimix"![]()
Establishment of Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China), establishment of Shionogi Singapore Pte. Ltd., change of royalty contract with AstraZeneca for Crestor, launch of postmenopausal vaginal atrophy treatment "Osphena" in the US, launch of antihypertensive drug "Ilutra"![]()
Start of Mid-term Management Strategy "Shionogi Growth Strategy 2020 (SGS2020)", launch of HIV infection treatment drug "Tebikei"![]()
Formulated a medium-term management plan aiming for growth as a drug discovery-oriented pharmaceutical company, setting ROE as a key indicator, and began efforts toward the management goals for 2020.![]()
Launch of HIV infection treatment drug "Trimek", allergen immunotherapy drug "Asitea", and thrombocytopenia treatment drug "Mulpeta"![]()
Update of the medium-term management plan "SGS2020", establishment of Shionogi Healthcare Co., Ltd., launch of high-cholesterol treatment drug "Crestor OD Tablets"![]()
Establishment of domestic group companies, Shionogi Carrier Development Center Inc., Shionogi Digital Science Inc., Shionogi Business Partners Inc., Shionogi Pharmacovigilance Center Inc., Shionogi Marketing Solutions Inc., launch of cancer pain treatment drug "Mesapain", launch of attention deficit/hyperactivity disorder treatment drug "Inchunib", launch of opioid-induced constipation treatment drug "Symproic" in the US, launch of "Swinproic", launch of sustained-release cancer pain treatment drug "OxyContin TR Tablets"![]()
Establishment of Shionogi Pharma Inc., establishment of European subsidiary Shionogi B.V., launch of anti-influenza virus drug "Zofluza", launch of thrombocytopenia treatment drug "Mulpleta" in the US, launch of anti-HIV drug "Jalka"![]()
Establishment of joint venture company "Stream Eye Inc." with M3 Inc., making UMN Pharma a consolidated subsidiary, opening of Shionogi Education and Training Center in Amagasaki City, launch of opioid-induced constipation treatment drug "Rizmoic" in Europe, launch of anti-influenza virus drug "Shufuxiao" in Taiwan, launch of attention deficit/hyperactivity disorder treatment drug "Vibance"![]()
Start of the mid-term management plan "Shionogi Transformation Strategy 2030 (STS2030)", establishment of joint venture "Ping An Shionogi Co., Ltd." with Ping An Insurance of China, full acquisition of Tetra Inc. in the US, acquisition of Nagase Pharmaceuticals, launch of gram-negative bacterial infection treatment drug "Fetroja" in the US, launch of "Fetcroja" in Europe![]()
Start of wastewater epidemiology survey services for COVID-19, launch of opioid-induced constipation treatment drug "Swinproic" in Taiwan![]()
Establishment of joint venture "AdvanSentinel Inc." with Shimadzu Corporation, establishment of general incorporated foundation "Shionogi Infectious Disease Research Promotion Foundation", development of SHIONOGI group brand and establishment of group brand mark, launch of COVID-19 treatment drug "Zokova"![]()
News
There is no news.